Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q38066972

about

Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease Elevated mRNA-levels of gonadotropin-releasing hormone and its receptor in plaque-bearing Alzheimer's disease transgenic mice Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?Benefits and risks of add-on therapies for Alzheimer's disease.Intrahippocampal Administration of Ibotenic Acid Induced Cholinergic Dysfunction via NR2A/NR2B Expression: Implications of Resveratrol against Alzheimer Disease Pathophysiology Retinal changes in the Tg-SwDI mouse model of Alzheimer's disease.Altered functional connectivity of the default mode network by glucose loading in young, healthy participants.Effects of Tea Catechins on Alzheimer's Disease: Recent Updates and Perspectives

P2860

Q26995351-981C5DBD-0CD4-4D96-951C-F3030C32E360 Q33999164-3109BF7F-D342-4A0C-8BAA-F17AB6DD80FE Q36273566-51DE481C-2516-4CC4-B60A-612BA0817F06 Q38132755-FF129632-A701-4B8E-83AF-CA3617A07152 Q38620338-9F3A71E5-6274-4806-BA57-8B4C31C281C6 Q40622685-B521778B-3E15-40E1-BC93-46C994B488DB Q47738091-3E59CA2A-A4B2-4808-AB04-6FCC92BE90BB Q55398487-CCEDDDE3-FCDC-47BE-99B0-B15BA21F1346 Q58691858-48F406CF-C3D5-47EC-BC3A-6098121E4D17

P2860

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.

http://www.wikidata.org/entity/Q38066972

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Rationale for combining glutam ...... atment of Alzheimer's disease.

@en

type

label

Rationale for combining glutam ...... atment of Alzheimer's disease.

@en

prefLabel

Rationale for combining glutam ...... atment of Alzheimer's disease.

@en

P1433

Q38066972-B06FCCF9-1570-4610-BE78-E3D4922A76CD

P1476

Q38066972-FEAC95A1-D19E-493E-8AF9-3DF2DA00CD9F

P2093

Q38066972-35557BA0-2753-4EB9-A161-FE8EEC20CDB4

Q38066972-88646470-8AEB-4389-B082-AD07DBC0248A

Q38066972-AA6E454C-BEFE-4C71-B442-E0CCDFAB55F7

P2860

Q38066972-02F75D9D-E5CE-45CA-AB14-F05679FD2036

Q38066972-035D2071-1E18-467F-8045-27F1FFE540D2

Q38066972-05E87A6D-3128-450B-BF41-CDD5C231212F

Q38066972-09F133E6-EF25-4896-BB2E-192318BC56BA

Q38066972-0CFC3CE8-6366-4414-AA56-C63F65A75F44

Q38066972-0E8A9791-0581-4674-80E2-9419A118F10B

Q38066972-10BAE831-9C03-4694-AF2C-9834F07D93C3

Q38066972-136C62D5-09AD-4B9A-8AA3-6A555D3E106F

Q38066972-158C2D6B-FA5C-44EE-A22A-687383815C03

Q38066972-159907B4-8B5E-48CF-97FB-9444D0526B4E

P304

Q38066972-CCE9ED83-032D-41A9-B62C-D0F02C593769

P31

Q38066972-2E6C4F06-46BB-443F-96C3-981AF862309D

Q38066972-7d70ec0b-eabb-424c-a11f-4ce35a501aa7

P356

Q38066972-321180D7-478A-4D07-805B-4E26FD6325B2

P433

Q38066972-B0270F0A-0534-4948-818C-3A08B94BD9A5

P478

Q38066972-F6D51CF0-D0B9-4046-B648-9D918CC3C88F

P577

Q38066972-FA6F48D1-5249-4AE4-ACFF-A84B5BA71834

P5875

Q38066972-E038DE6D-1E65-4B5E-A650-22D1E72DF152

P698

Q38066972-FBE8022D-5066-47AB-A5FA-D9866D62FF80

P921

Q38066972-87A96833-56C7-4497-BC4A-F046C34DFC82

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Rationale for combining glutam ...... atment of Alzheimer's disease.

@en

P2093

Chris G Parsons

http://www.w3.org/2001/XMLSchema#string

Paul T Francis

http://www.w3.org/2001/XMLSchema#string

Roy W Jones

http://www.w3.org/2001/XMLSchema#string

P2860

The cholinergic hypothesis of Alzheimer's disease: a review of progress

Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors

Long-term course and effectiveness of combination therapy in Alzheimer disease

Neuropathological stageing of Alzheimer-related changes

The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus

Regulation of NMDA receptor trafficking by amyloid-beta

Central cholinesterase inhibition enhances glutamatergic synaptic transmission.

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.

Nicotinic receptor abnormalities in Alzheimer's disease.

P304

1351-1365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.12.124

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233907897

http://www.w3.org/2001/XMLSchema#string

P698

23234396

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease